Bookmark and Share

Compound Summary for: CID 5311

vorinostat

Also known as: SAHA; Zolinza; suberoylanilide hydroxamic acid; 149647-78-9; Suberanilohydroxamic acid; N-hydroxy-N'-phenyloctanediamide; SAHA cpd
Molecular Formula: C14H20N2O3   Molecular Weight: 264.3202   InChIKey: WAEXFXRVDQXREF-UHFFFAOYSA-N
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Biomedical Effects and Toxicity
Safety and Handling
Exposure Standards and Regulations
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _